初级保健中抗骨质疏松药物急性心肌梗死风险比较:英国临床实践研究数据库与加泰罗尼亚SIDIAP数据库倾向匹配队列发现的Meta分析
本研究基于英国CPRD(1995-2014年)和加泰罗尼亚SIDIAP(2006-2014年)两个初级保健数据库,采用倾向匹配队列研究和Meta分析,比较阿仑膦酸钠与其他口服双膦酸盐、雷奈酸锶及选择性雌激素受体调节剂(SERM)使用者的急性心肌梗死风险。CPRD中其他双膦酸盐较阿仑膦酸钠风险增加10%,两库Meta分析显示风险增加9%;合并糖尿病和慢性肾脏病的SERM使用者风险升高。结果支持阿仑膦酸钠作为骨质疏松一线治疗的心血管安全性。
要点
- CPRD中其他双膦酸盐使用者急性心肌梗死风险较阿仑膦酸钠使用者增加10%。
- CPRD与SIDIAP合并Meta分析显示其他双膦酸盐较阿仑膦酸钠风险增加9%。
- 合并糖尿病和慢性肾脏病的SERM使用者急性心肌梗死风险升高。
核心结论
- 本研究为接受骨质疏松治疗患者的急性心肌梗死风险提供了额外数据。
- 结果支持阿仑膦酸钠作为骨质疏松一线治疗选择的心血管安全性。
研究设计与样本
- 本研究为倾向匹配队列研究和Meta分析,数据来自英国NHS的CPRD(1995-2014年)和加泰罗尼亚医疗SIDIAP(2006-2014年)两个初级保健记录数据库。
- 以阿仑膦酸钠使用者为参照组,经倾向评分匹配基线特征后,与其他口服双膦酸盐、雷奈酸锶及SERM使用者比较。
- 采用多重插补处理混杂因素缺失数据,采用竞争风险模型计算相对风险(亚分布风险比SHR),各国数据单独分析后行Meta分析。
主要发现
- 在CPRD中,其他双膦酸盐使用者较阿仑膦酸钠使用者急性心肌梗死风险增加10%。
- CPRD与SIDIAP结果的Meta分析显示,其他双膦酸盐使用者较阿仑膦酸钠使用者风险增加9%。
- 敏感性分析显示,合并糖尿病和慢性肾脏病的SERM使用者风险升高。
临床怎么用
- 原文结论认为结果支持阿仑膦酸钠作为骨质疏松一线治疗选择的心血管安全性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The aim of this study was to evaluate the risk of acute myocardial infarction in patients taking osteoporosis medication. Patients were taken from the SIDIAP or CPRD database and were matched using propensity scores. Patients with diabetes and chronic kidney disease taking SERMs were at an increased risk. The results favour the cardiovascular safety of alendronate as a first-line choice for osteoporosis treatment. INTRODUCTION: This study aims to evaluate the comparative safety of anti-osteoporosis drugs based on the observed risk of acute myocardial infarction while on treatment in a primary care setting. METHODS: This is a propensity-matched cohort study and meta-analysis. This study was conducted in two primary care record databases covering UK NHS (CPRD) and Catalan healthcare (SIDIAP) patients during 1995-2014 and 2006-2014, respectively. The outcome was acute myocardial infarction while on treatment. Users of alendronate (reference group) were compared to those of (1) other oral bisphosphonates (OBP), (2) strontium ranelate (SR), and (3) selective oestrogen receptor modulator (SERM), after matching on baseline characteristics (socio-demographics, fracture risk factors, comorbidities, and concomitant drug use) using propensity scores. Multiple imputation was used to handle missing data on confounders and competing risk modelling for the calculation of relative risk (sub-distribution hazard ratios (SHR)) according to therapy. Country-specific data were analysed individually and meta-analysed. RESULTS: A 10% increased risk of acute myocardial infarction was found in users of other bisphosphonates as compared to alendronate users within CPRD. The meta-analysis of CPRD and SIDIAP results showed a 9% increased risk in users of other bisphosphonate as compared to alendronate users. Sensitivity analysis showed SERMS users with diabetes and chronic kidney disease were at an elevated risk. CONCLUSIONS: This study provides additional data on the risk of acute myocardial infarction in patients receiving osteoporosis treatment. The results favour the cardiovascular safety of alendronate as a first-line choice for osteoporosis treatment.
引用
- Khalid S, Calderon-Larranaga S, Sami A, et al. Comparative risk of acute myocardial infarction for anti-osteoporosis drugs in primary care: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database. Osteoporos Int. 2022. PMID: 35138412. doi:10.1007/s00198-021-06262-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。